Moonshot AI 将 Kimi 模型重心从编程转向科学

由于 Moonshot AI 认为编程领域的回报正在递减,这家北京初创公司正将其 Kimi 语言模型转向生物学、化学和制药研究。国际业务总监 Giacomo Ficari 在里斯本 Web Summit 上表示,科学领域需要比法律、金融或编程更聪明的 AI 模型。
北京初创公司 DP Technology 正在将 Kimi K3.1 Pro 集成到其研究助手 BioMaster 中。在一项测试中,该 AI 分析了来自 3,696 个小鼠胰腺细胞的基因数据,并在 90 分钟内标记出 100 个候选基因,而人类完成这项工作估计需要 4 小时。
完全独立的突破仍遥遥无期。在 TCSExam 这一包含 100 道题的理论计算机科学基准测试中,领先模型能够生成可验证的证明,但无法单独破解任何开放猜想。美国竞争对手也遇到了类似的局限。Anthropic 的 Claude 在 9 月发现了一个酶系统,但数学家批评了 OpenAI 宣称的数学和物理学突破。制药行业也尚未完全买账。Citi 6 月对 50 位美国研究负责人进行的一项调查发现,72% 已在广泛使用 AI,但只有 24% 预计它会显著提高药物开发的成功率。
没有炒作的 AI 新闻——由人类精选
译文由英文原文机器翻译,术语按行业惯例统一,可在文末展开原文核对。
查看英文原文(Moonshot AI pivots Kimi models from coding to science as benchmark gains flatten)
Because Moonshot AI sees diminishing returns in coding, the Beijing startup is redirecting its Kimi language models toward biology, chemistry, and pharma research. International director Giacomo Ficari said at the Web Summit in Lisbon that science demands smarter AI models than law, finance, or code.
Beijing startup DP Technology is integrating Kimi K3.1 Pro into its research assistant BioMaster. In one test, the AI analyzed gene data from 3,696 mouse pancreatic cells and flagged 100 candidate genes in 90 minutes instead of an estimated four hours of human work.
Fully independent breakthroughs are still a long way off. On TCSExam, a 100-problem theoretical CS benchmark, leading models produced verifiable proofs but couldn't crack any open conjectures alone. US rivals hit similar limits. Anthropic's Claude found an enzyme system in September, but mathematicians criticized OpenAI's claimed math and physics breakthroughs. The pharma industry isn't sold yet either. A June Citi survey of 50 US research leaders found 72 percent already using AI broadly, but only 24 percent expect it to noticeably improve drug development success rates.
AI News Without the Hype – Curated by Humans
原文为英文,正文由自动抓取并保留原文。
原文发布于 The Decoder(Moonshot AI pivots Kimi models from coding to science as benchmark gains flatten),标题、摘要与正文由机器翻译,术语按行业惯例统一,未经人工逐句校订。